## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D	.C. 20549
---------------	-----------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
--

OMB APPROVAL										
OMB Number: 3235-028										
Estimated average burden										
hours per response										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol TScan Therapeutics, Inc. [ TCRX ]							5. I (Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
SOUTHWELL DAVID P				-			1						X Director	•		10% Ow	ner
(Last)	(F	irst)	(Middle)	3	Date of Earliest Transaction (Month/Day/Year)							$\dashv$	X Officer below)	(give title		Other (sp below)	pecify
C/O TSCAN THERAPEUTICS, INC.				0	02/02/2023							Chief Executive Officer					
830 WIN	TER STRE	EET		L													
				4	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) WALTH	AM M	ΙA	02451										,	ed by One	Reporting	g Person	
,			02 101										Form fil Person	ed by More	than On	e Reporti	ng
(City)	(S	tate)	(Zip)		1 03011												
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date				. Transacti Date Month/Day	Execution Date,		3. Transaction Code (Instr.) 8) 4. Securities Acqu Disposed Of (D) (In				Beneficia Owned F	s Illy ollowing	6. Owner Form: Dir (D) or Ind (I) (Instr.	rect li lirect E 4) C	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	ount (A) or (D)		Transacti	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	Code (Ins				6. Date Exercisa Expiration Date (Month/Day/Yea		of Securities		ties ig e Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	ly Ov Fo Dii or (I)	vnership rm: rect (D) Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)		Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	(3)		
Stock Option (Right to Buy)	\$1.81	02/02/2023		A		100,000		(1)	02	2/01/2033	Voting Common Stock	100,000	\$0.00	100,000	0	D	

## **Explanation of Responses:**

1. The shares subject to this option vest over 4 years of service following February 2, 2023, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.

## Remarks:

/s/ David P. Southwell

02/06/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.